Related Experiment Video
Updated: Sep 18, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B-Cell Lymphoma: A Retrospective Study
Zhenbo Hou1,2, Kebing Chen1,2, Yuling Lu3
1Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Background:
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma with heterogeneous clinical features and survival outcomes. Although most patients respond favorably to modern immunochemotherapy, reliable baseline prognostic indicators remain insufficiently defined.
Methods:
We retrospectively analyzed 424 patients with histologically confirmed PB-DLBCL. Clinical characteristics, treatment patterns and survival outcomes were evaluated. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Prognostic factors were assessed by univariate and multivariate Cox regression analyses.
Results:
With a median follow-up of 36 months, the 3 year OS and PFS rates were 81.3% and 63.3%, respectively. In multivariate analysis, high-risk International Prognostic Index (IPI; score 3-5) was independently associated with inferior OS (HR 2.06, 95% CI 1.24-3.43, p = 0.006). For PFS, hypoalbuminemia (< 40 g/L) emerged as an independent predictor (HR 1.44, 95% CI 1.03-2.02, p = 0.035). Although failure to achieve complete remission and high Deauville score were associated with worse outcomes in univariate analyses, these post-treatment variables were not included in multivariable models.
Conclusion:
PB-DLBCL often presents with advanced disease but demonstrates generally favorable survival in the rituximab era. Baseline IPI remains a robust predictor of OS, while hypoalbuminemia independently predicts disease progression.